TEVA at a glance
Teva Pharmaceutical Industries Ltd (TEVA, SEC CIK 818686) filed its latest 10-K annual report on February 3, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Teva Pharmaceutical Industries Ltd (TEVA) reported revenue of $17.3 billion (up 4.3% from FY2024) and net income of $1.4 billion. Diluted EPS was $1.21.
- As of June 30, 2026, 36 institutional investment managers tracked by SignalX reported holding Teva Pharmaceutical Industries Ltd (TEVA) shares worth $5.7 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Sabag Mark on November 12, 2026 of 44,710 shares at $44.14 per share.
- In the last 90 days, TEVA insiders reported 0 open-market purchases ($0) and 14 open-market sales ($32.9M) on Form 4, a net sale of $32.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $17.3B
- +4.3% vs prior year
- Insiders · 90 days
- 0 buys · 14 sells
- Net −$32.9M
- 13F holders
- 36 funds
- $5.7B · +2 vs prior quarter
- Latest 8-K
- Nov 18, 2026
- Item 5.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- Carried-forward regulatory risk, pharmaceutical compliance obligations remain material
- Carried-forward operational risk, competitive pressures may affect performance
- Carried-forward financial risk, debt and liquidity exposures remain relevant
Management Discussion & Analysis
- Revenue $4,395M, down 2% YoY from $4,395M, driven by lower generic sales, especially lenalidomide
- Gross margin 55.5% vs 51.4%; operating margin 16.2% vs 19.7%, with operating income $714M vs $882M
- Best segment: Europe revenue $1,319M, up 7%, profit $420M, up 39%; worst: U.S. revenue $1,870M, down 11%
- Cash $4,085M vs $3,556M at December 31; operating cash flow $241M vs $369M, free cash flow $495M vs $515M
- Headwinds: tariffs, geopolitical supply-chain disruptions, generic competition; AUSTEDO prices reduced for eligible Medicare patients January 1, 2027
AI summary of the TEVA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Dr. Eric Hughes resigning immediately as EVP, Global R&D and Chief Medical Officer
- Hughes remaining for several months to support transition
Item 7.01: Regulation FD Disclosure
- Dr. Eric Hughes will leave Teva, creating a senior leadership transition
- Departure details and succession plans are contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- R&D chief Eric Hughes departing for an external role, creating near-term leadership transition risk
- David Gardiner named interim R&D transition lead, reporting directly to CEO Richard Francis
Item 2.02: Results of Operations and Financial Condition
- Teva announced financial results for the quarter ended September 30, 2026
- Full results, including operating performance and outlook, are contained in Exhibit 99.1‑
Item EX-99.1: Item EX-99.1
- Q3 revenue $4.395B, down 2% YoY as U.S. generic revenue fell 39%, primarily from lenalidomide competition
- Innovative brands generated approximately $1.1B, up 33% locally, supporting higher 2026 outlooks for AUSTEDO, AJOVY and UZEDY
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Dr. David J. Brailer elected independent director, effective November 3, 2026, through Teva’s 2027 annual meeting
- Expected committee assignments: Human Resources and Compensation, Compliance
AI summaries of TEVA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TEVA
Don't miss the next TEVA filing
- Alerts as it files. A push when TEVA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TEVA, by share count.
- Ask anything. An AI agent that reads every TEVA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Bergwerk Dov | M | Nov 15, 2026 | 8,370 | - |
| Bergwerk Dov | M | Nov 15, 2026 | 8,370 | - |
| Sabag Mark | Sell | Nov 12, 2026 | 44,710 | $44.14 |
| Sabag Mark | M | Nov 12, 2026 | 44,710 | - |
| Sabag Mark | M | Nov 12, 2026 | 44,710 | $34.90 |
| Daniell Richard | M | Nov 11, 2026 | 20,003 | - |
| Daniell Richard | M | Nov 11, 2026 | 20,003 | $34.70 |
| Daniell Richard | Sell | Nov 11, 2026 | 20,003 | $42.80 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $16.5B | $17.3B |
| Gross Profit | - | $8.1B | $8.9B |
| Operating Income | - | -$303.0M | $2.2B |
| Net Income | - | -$1.6B | $1.4B |
| Gross Margin | - | 48.7% | 51.8% |
| Op. Margin | - | -1.8% | 12.5% |
| Net Margin | - | -9.9% | 8.2% |
| Balance Sheet | |||
| Total Assets | $43.5B | $39.3B | $40.7B |
| Equity | $7.5B | $5.4B | $7.9B |
| ROE | - | -30.5% | 17.8% |
| Per Share | |||
| EPS | $-0.50 | $-1.45 | $1.21 |
| Cash Flow | |||
| Operating CF | $1.4B | $1.2B | $1.6B |
Source: XBRL data in Teva Pharmaceutical Industries Ltd (TEVA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TEVA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 36 | $5.69B |
| Q1 2026 | 34 | $4.93B |
| Q4 2025 | 36 | $5.17B |
| Q3 2025 | 38 | $3.27B |
| Q2 2025 | 36 | $3.35B |
| Q1 2025 | 31 | $2.79B |
| Q4 2024 | 29 | $3.52B |
- Citigroup+1.69M (+204%)
- Millennium Management+1.37M (+72%)
- Goldman Sachs Group+1.30M (+27%)
- State Street Corp+1.15M (+6%)
- T. Rowe Price Group+1.05M (+165%)
- FMR LLC (Fidelity)−2.87M (-9%)
- BlackRock−1.24M (-2%)
- Morgan Stanley−457.5K (-6%)
- Two Sigma Investments−135.5K (-37%)
- Raymond James Financial−124.1K (-7%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 240 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TEVA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 18, 2026 | - | Analysis | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 8-K | Sep 16, 2026 | - | Analysis | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 8-K | Sep 11, 2026 | - | Analysis | - |
| 8-K | Sep 3, 2026 | - | Analysis | - |
| 8-K | Sep 3, 2026 | - | Analysis | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
TEVA SEC filings: frequently asked questions
Are TEVA insiders buying or selling?
In the last 90 days, Teva Pharmaceutical Industries Ltd (TEVA) officers, directors and 10% owners reported no open-market purchases and 14 open-market sales worth $32.9 million by 7 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TEVA stock?
As of June 30, 2026, the largest Teva Pharmaceutical Industries Ltd (TEVA) holders among the 13F filers tracked by SignalX were BlackRock ($2.2 billion), FMR LLC (Fidelity) ($1.0 billion), State Street Corp ($641.6 million), Northern Trust ($269.6 million), Morgan Stanley ($236.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TEVA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Teva Pharmaceutical Industries Ltd (TEVA) reported revenue of $17.3 billion (up 4.3% from FY2024) and net income of $1.4 billion. Diluted EPS was $1.21. The figures come from the XBRL data in the 10-K.
What did TEVA report in its latest 8-K?
Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K on November 18, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 7.01 (Regulation FD Disclosure). Dr. Eric Hughes resigning immediately as EVP, Global R&D and Chief Medical Officer.
What are the latest TEVA SEC filings?
Teva Pharmaceutical Industries Ltd (TEVA) filed its latest 10-K annual report on February 3, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on November 17, 2026.
What is TEVA's SEC CIK number?
Teva Pharmaceutical Industries Ltd (TEVA)'s SEC Central Index Key (CIK) is 818686. EDGAR lists every TEVA filing under that number.
Ask anything about TEVA
The research agent reads TEVA's filings, financials, insider trades and 13F holders, then answers with sources.